T-Therapeutics Raises $133m Series B for TCR Bispecific Programmes
T-Therapeutics has raised $133m in an oversubscribed Series B round led by Advent Life Sciences and British Business Bank, with Johnson & Johnson Innovation, Lilly, Samsara BioCapital and M Ventures joining as new investors. The Cambridge company will use the funds to take two TCR-CD3 bispecific programmes, one in oncology and one in autoimmune disease, into the clinic.